Esperion Therapeutics (NASDAQ:ESPR – Get Free Report)‘s stock had its “buy” rating reaffirmed by equities researchers at HC Wainwright in a report issued on Thursday,Benzinga reports. They presently have a $16.00 price objective on the biopharmaceutical company’s stock.
Separately, StockNews.com lowered shares of Esperion Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, November 15th.
Check Out Our Latest Stock Analysis on ESPR
Esperion Therapeutics Stock Performance
Institutional Trading of Esperion Therapeutics
A number of institutional investors have recently bought and sold shares of ESPR. Wasatch Advisors LP lifted its stake in shares of Esperion Therapeutics by 38.4% during the third quarter. Wasatch Advisors LP now owns 23,346,013 shares of the biopharmaceutical company’s stock worth $38,521,000 after buying an additional 6,483,070 shares during the period. Geode Capital Management LLC lifted its position in Esperion Therapeutics by 4.1% during the 3rd quarter. Geode Capital Management LLC now owns 4,331,314 shares of the biopharmaceutical company’s stock worth $7,148,000 after acquiring an additional 171,609 shares during the period. Marshall Wace LLP grew its stake in Esperion Therapeutics by 94.2% during the 2nd quarter. Marshall Wace LLP now owns 4,303,596 shares of the biopharmaceutical company’s stock valued at $9,554,000 after purchasing an additional 2,087,635 shares during the last quarter. State Street Corp increased its holdings in shares of Esperion Therapeutics by 2.7% in the third quarter. State Street Corp now owns 3,854,314 shares of the biopharmaceutical company’s stock valued at $6,360,000 after purchasing an additional 99,802 shares during the period. Finally, Connor Clark & Lunn Investment Management Ltd. raised its stake in shares of Esperion Therapeutics by 71.0% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 711,278 shares of the biopharmaceutical company’s stock worth $1,174,000 after purchasing an additional 295,378 shares during the last quarter. 47.39% of the stock is currently owned by institutional investors and hedge funds.
Esperion Therapeutics Company Profile
Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.
Read More
- Five stocks we like better than Esperion Therapeutics
- What Does Downgrade Mean in Investing?
- FinWise Bancorp’s CEO Talks Strategy Behind Fintech Success
- How to Capture the Benefits of Dividend Increases
- Broadcom: Turning the Mag 7 Into 8 Trillion-Dollar Tech Giants
- Using the MarketBeat Dividend Tax Calculator
- SoundHound AI: Can Its Meteoric Rise Sustain Into 2025?
Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.